Abcg2/Bcrp1 Mediates the Polarized Transport of Antiretroviral Nucleosides Abacavir and Zidovudine

The bioavailability and targeted distribution of abacavir (ABC) and zidovudine (AZT) to viral reservoirs may be influenced by efflux transporters. The purpose of this study was to characterize the interaction of these nucleoside reverse transcriptase inhibitors with the Abcg2/Bcrp1 transporter, the murine homolog of human breast cancer resistance protein (BCRP), using a Bcrp1-transfected Madin-Darby canine kidney II cell model. Intracellular accumulation of ABC and AZT was significantly reduced by ∼90% and ∼70%, respectively, in Bcrp1-transfected cells compared with the wild-type cells. Both ABC and AZT showed significantly increased basolateral-to-apical (B-to-A) and decreased apical-to-basolateral (A-to-B) transport in Bcrp1 cells compared with wild-type directional flux. The efflux ratio (ratio of B-to-A to A-to-B) in Bcrp1-transfected cells was 22 for ABC and 11 for AZT. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) inhibited this difference in accumulation between the two cell variants with an EC50 of 1.32 ± 0.3 μM for ABC and 0.31 ± 0.1 μM for AZT. Potent and highly cooperative inhibition by Ko143 (3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indol-3-yl)-propionic acid tert-butyl ester) was observed with an EC50 of 121 ± 5 nM for ABC and 19.2 ± 1.5 nM for AZT (Hill coefficient ∼3–6). Probenecid, an organic anion inhibitor known to influence AZT biodistribution, had no effect on cellular accumulation in the Bcrp1 model. These studies characterize the Bcrp1-mediated transport of ABC and AZT and show that prototypical BCRP inhibitors GF120918 and Ko143 can inhibit the Bcrp1-mediated transport of these important antiretroviral compounds. The functional expression of BCRP at critical barriers, such as the intestinal enterocytes, brain capillary endothelium, and target lymphocytes, could influence the bioavailability and targeted delivery of these drugs to sanctuary sites.

[1]  O. Bagasra,et al.  Cellular reservoirs of HIV‐1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry , 1996, AIDS.

[2]  M. J. van de Vijver,et al.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. , 2001, Cancer research.

[3]  R. Polk,et al.  Pharmacokinetics of [14C]Abacavir, a Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Inhibitor, Administered in a Single Oral Dose to HIV-1-Infected Adults: a Mass Balance Study , 1999, Antimicrobial Agents and Chemotherapy.

[4]  R. Pomerantz,et al.  Twenty years of therapy for HIV-1 infection , 2003, Nature Medicine.

[5]  G. Folkers,et al.  Identification of a novel human organic anion transporting polypeptide as a high affinity thyroxine transporter. , 2002, Molecular endocrinology.

[6]  Masahiko Watanabe,et al.  Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte‐derived soluble factor(s) , 2004, Journal of neurochemistry.

[7]  Kelly H. Jordan,et al.  P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. , 2003, Journal of pharmaceutical sciences.

[8]  L. Doyle,et al.  A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Y. Sugiyama,et al.  In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. , 1997, The Journal of pharmacology and experimental therapeutics.

[10]  A. Pardee.  Role Reversal for Anticancer Agents , 2002, Cancer biology & therapy.

[11]  J. Schellens,et al.  Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.

[12]  S. A. Thomas,et al.  Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. , 2001, The Journal of pharmacology and experimental therapeutics.

[13]  Yaron Werber.  HIV drug market , 2003, Nature reviews. Drug discovery.

[14]  C. Ezzell.  AZT given the green light for clinical treatment of AIDS , 1987, Nature.

[15]  J. Schellens,et al.  Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2) , 2005, Cancer Chemotherapy and Pharmacology.

[16]  Xin Wang,et al.  Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. , 2004, Biochemical pharmacology.

[17]  A. Karim.  The pharmacokinetics of Norpace. , 1975, Angiology.

[18]  S. A. Thomas,et al.  The distribution of the anti‐HIV drug, 2′3′‐dideoxycytidine (ddC), across the blood–brain and blood–cerebrospinal fluid barriers and the influence of organic anion transport inhibitors , 2002, Journal of neurochemistry.

[19]  J. Yamashita,et al.  Expression of Multidrug Resistance-associated Protein (MRP) in Human Gliomas , 2000, Journal of Neuro-Oncology.

[20]  D. Dickson,et al.  Human immunodeficiency virus-1 infection of the nervous system: an autopsy study of 268 adult, pediatric, and fetal brains. , 1991, Human pathology.

[21]  H. Kessler,et al.  Therapeutic Drug Monitoring of the HIV/AIDS Drugs Abacavir, Zidovudine, Efavirenz, Nevirapine, Indinavir, Lopinavir, and Nelfinavir , 2003, Pharmacology.

[22]  N. Shaik,et al.  Drug efflux transporters in the CNS. , 2003, Advanced drug delivery reviews.

[23]  H. McClure,et al.  Pharmacokinetics of 3'-azido-3'-deoxythymidine and its catabolites and interactions with probenecid in rhesus monkeys , 1991, Antimicrobial Agents and Chemotherapy.

[24]  M. Melamed,et al.  Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. , 1990, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[25]  D. Dormont,et al.  Atp Binding Cassette Multidrug Transporters Limit the Anti-HIV Activity of Zidovudine and Indinavir in Infected Human Macrophages , 2003, Antiviral therapy.

[26]  L. Boone,et al.  1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity , 1997, Antimicrobial agents and chemotherapy.

[27]  J. Schellens,et al.  Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. , 2000, Cancer research.

[28]  R. Robey,et al.  Flow cytometric analysis of breast cancer resistance protein expression and function. , 2002, Cytometry.

[29]  J. Schellens,et al.  Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.

[30]  R. Sawchuk,et al.  Investigation of distribution, transport and uptake of anti-HIV drugs to the central nervous system. , 1999, Advanced drug delivery reviews.

[31]  E. De Clercq,et al.  Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[32]  P. Sinko,et al.  P-Glycoprotein and Mutlidrug Resistance-Associated Proteins Limit the Brain Uptake of Saquinavir in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[33]  S. Wong,et al.  Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. , 1993, The Journal of pharmacology and experimental therapeutics.

[34]  Yi Zhang,et al.  HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2) , 2004, Journal of Pharmacology and Experimental Therapeutics.

[35]  M. Barrand,et al.  Localisation of breast cancer resistance protein in microvessel endothelium of human brain , 2002, Neuroreport.

[36]  E. Wang,et al.  Cooperativity in the inhibition of P-glycoprotein-mediated daunorubicin transport: evidence for half-of-the-sites reactivity. , 2000, Archives of biochemistry and biophysics.

[37]  F. Clavel,et al.  Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir. , 1997, AIDS.

[38]  R. Sawchuk,et al.  Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. , 1997, Journal of pharmaceutical sciences.

[39]  Xin Wang,et al.  Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. , 2003, Molecular pharmacology.